Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18177032 | 0.71 | HTR1A (0.37) | HTR1ADRD2HTR2AHTR7ALDH1A1 | |
| SCHEMBL13026175 | 0.71 | HTR1A (0.37) | HTR1ADRD2HTR2AHTR7ALDH1A1 | |
| SCHEMBL16473919 | 0.71 | GRIA1 (0.33) | — | |
| SCHEMBL1704564 | 0.69 | — | — | |
| SCHEMBL1753761 | 0.69 | — | — | |
| SCHEMBL16672980 | 0.68 | HTR1A (0.34) | HTR1ADRD2HTR2AHTR7ALDH1A1 | |
| SCHEMBL5474386 | 0.67 | ALDH1A1 (0.33) | HTR1ADRD2HTR2AHTR7ALDH1A1 | |
| SCHEMBL18297973 | 0.67 | ALDH1A1 (0.34) | HTR1ADRD2HTR2AHTR7ALDH1A1 | |
| SCHEMBL1909000 | 0.65 | CA2 (0.32) | — | |
| SCHEMBL17452118 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230330245-A1 | ANTIBODY-EXATECAN CONJUGATES | SYNAFFIX B.V. (NL) | 2023-10-19 | — | — | US | disclosed |
| US-20230158155-A1 | Cell Surface Receptor Binding Compounds and Conjugates | LYCIA THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158155-A1 | Cell Surface Receptor Binding Compounds and Conjugates | M6PR, ASGR1, IGF2R | HTR1A 2636/4885DRD2 1929/4885HTR2A 1870/4885 |
| US-20230330245-A1 | ANTIBODY-EXATECAN CONJUGATES | ERBB3, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, IL23R | HTR1A 1858/4885DRD2 1078/4885HTR2A 2331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.